These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 30222465)

  • 1. Methods and Issues to Consider for Detection of Safety Signals From Spontaneous Reporting Databases: A Report of the DIA Bayesian Safety Signal Detection Working Group.
    Gould AL; Lystig TC; Lu Y; Fu H; Ma H
    Ther Innov Regul Sci; 2015 Jan; 49(1):65-75. PubMed ID: 30222465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety related drug-labelling changes: findings from two data mining algorithms.
    Hauben M; Reich L
    Drug Saf; 2004; 27(10):735-44. PubMed ID: 15350157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accounting for multiplicity in the evaluation of "signals" obtained by data mining from spontaneous report adverse event databases.
    Gould AL
    Biom J; 2007 Feb; 49(1):151-65. PubMed ID: 17342957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A signal detection method for temporal variation of adverse effect with vaccine adverse event reporting system data.
    Cai Y; Du J; Huang J; Ellenberg SS; Hennessy S; Tao C; Chen Y
    BMC Med Inform Decis Mak; 2017 Jul; 17(Suppl 2):76. PubMed ID: 28699543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database.
    Szarfman A; Machado SG; O'Neill RT
    Drug Saf; 2002; 25(6):381-92. PubMed ID: 12071774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of Disproportionality Analysis of Pharmacovigilance Databases in Safety Regulatory Actions: a Systematic Review.
    Dias P; Penedones A; Alves C; Ribeiro CF; Marques FB
    Curr Drug Saf; 2015; 10(3):234-50. PubMed ID: 26219291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative performance of two quantitative safety signalling methods: implications for use in a pharmacovigilance department.
    Almenoff JS; LaCroix KK; Yuen NA; Fram D; DuMouchel W
    Drug Saf; 2006; 29(10):875-87. PubMed ID: 16970511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Criteria revision and performance comparison of three methods of signal detection applied to the spontaneous reporting database of a pharmaceutical manufacturer.
    Matsushita Y; Kuroda Y; Niwa S; Sonehara S; Hamada C; Yoshimura I
    Drug Saf; 2007; 30(8):715-26. PubMed ID: 17696584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Useful Interplay Between Spontaneous ADR Reports and Electronic Healthcare Records in Signal Detection.
    Pacurariu AC; Straus SM; Trifirò G; Schuemie MJ; Gini R; Herings R; Mazzaglia G; Picelli G; Scotti L; Pedersen L; Arlett P; van der Lei J; Sturkenboom MC; Coloma PM
    Drug Saf; 2015 Dec; 38(12):1201-10. PubMed ID: 26370104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of two drug safety signals in a pharmacovigilance data mining framework.
    Tubert-Bitter P; Bégaud B; Ahmed I
    Stat Methods Med Res; 2016 Apr; 25(2):615-29. PubMed ID: 23070598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
    Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
    MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Analysis of Spontaneously Reported Adverse Events].
    Nakamura M
    Yakugaku Zasshi; 2016; 136(4):549-56. PubMed ID: 27040337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multinomial modeling and an evaluation of common data-mining algorithms for identifying signals of disproportionate reporting in pharmacovigilance databases.
    Johnson K; Guo C; Gosink M; Wang V; Hauben M
    Bioinformatics; 2012 Dec; 28(23):3123-30. PubMed ID: 23064001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of consumer reporting on signal detection: using disproportionality analysis.
    Hammond IW; Rich DS; Gibbs TG
    Expert Opin Drug Saf; 2007 Nov; 6(6):705-12. PubMed ID: 17967159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative methods in pharmacovigilance: focus on signal detection.
    Hauben M; Zhou X
    Drug Saf; 2003; 26(3):159-86. PubMed ID: 12580646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using time-to-onset for detecting safety signals in spontaneous reports of adverse events following immunization: a proof of concept study.
    Van Holle L; Zeinoun Z; Bauchau V; Verstraeten T
    Pharmacoepidemiol Drug Saf; 2012 Jun; 21(6):603-10. PubMed ID: 22383219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early postmarketing drug safety surveillance: data mining points to consider.
    Hauben M
    Ann Pharmacother; 2004 Oct; 38(10):1625-30. PubMed ID: 15304626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of statistical signal detection methods within and across spontaneous reporting databases.
    Candore G; Juhlin K; Manlik K; Thakrar B; Quarcoo N; Seabroke S; Wisniewski A; Slattery J
    Drug Saf; 2015 Jun; 38(6):577-87. PubMed ID: 25899605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential use of data-mining algorithms for the detection of 'surprise' adverse drug reactions.
    Hauben M; Horn S; Reich L
    Drug Saf; 2007; 30(2):143-55. PubMed ID: 17253879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolving paradigms in pharmacovigilance.
    Brewster W; Gibbs T; Lacroix K; Murray A; Tydeman M; Almenoff J
    Curr Drug Saf; 2006 May; 1(2):127-34. PubMed ID: 18690923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.